Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of atezolizumab vs docetaxel in previously treated NSCLC
jRCT2080222480Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised trial of atezolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: overall survival. Started May 2014; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080222480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222480.